Drug Profile
Research programme: African trypanosomiasis therapies - Pfizer/DNDi/SCYNEXIS
Alternative Names: AN-2920; AN-3520; AN-4169; SCYX-1330682; SCYX-1608210; SCYX-6759Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; SCYNEXIS
- Developer Drugs for Neglected Diseases Initiative Foundation; Pfizer; SCYNEXIS
- Class Benzamides; Organic boron compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in African-trypanosomiasis in USA (PO)
- 23 Nov 2018 Early research for African trypanosomiasis therapies is ongoing in USA (DNDi pipeline, November 2018)
- 04 Nov 2017 No recent reports of development identified for early research in African trypanosomiasis in USA (PO)